General MedicationsSUBCUTANEOUSGeneric
FORTEO
TERIPARATIDE
Standard Dose
0.75MG/3ML (0.25MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview FORTEO is listed in Drugs@FDA under application 021318 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TERIPARATIDE Form and strength SOLUTION;SUBCUTANEOUS - 0.75MG/3ML (0.25MG/ML) Sponsor LILLY Submission history Latest submission status date: 2024-07-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview FORTEO is listed in Drugs@FDA under application 021318 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TERIPARATIDE Form and strength SOLUTION;SUBCUTANEOUS - 0.75MG/3ML (0.25MG/ML) Sponsor LILLY Submission history Latest submission status date: 2024-07-24 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.